RxDoctor Payments DataLook up a doctor →

Amit Sachdev

Neurology · East Lansing, MINPI 1962720797

Payments from drug & device makers

$1,632,897in general payments, 2019–2025

Across 1,009 payments — averaging $1618.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$788K
  • UCB SA$227K
  • AstraZeneca$192K
  • Argenx US, Inc.$131K
  • Sanofi US Services Inc.$69K
  • UCB, Inc.$55K
  • plus $171K from 47 others
$1,181in research payments, 2019–2025

Across 4 payments — averaging $295.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$1K

What the payments were for

  • Consulting fees$68,62318%
  • Speaking & faculty fees$240,80464%
  • Grants$290%
  • Travel & lodging$53,51014%
  • Food & beverage$11,2653%
  • Education$890%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,632,897 in reported general payments places this provider in the 95th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$51,065
Medicare patients
170
Services billed
7,353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab47$2,449,238
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5079$1,033,881
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5073$773,539
Gamunex-CImmune Globul G/Gly/Iga Avg 4668$581,903
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5026$170,850
Pyridostigmine Bromide118$24,652
Pyridostigmine Bromide ErPyridostigmine Bromide30$17,490
Mycophenolate Mofetil43$6,909
Gabapentin143$2,428
Levetiracetam31$1,353
Pregabalin49$1,281
Duloxetine Hcl58$1,031
Prednisone102$1,005
Donepezil Hcl28$940
Baclofen29$814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$191,979$2,449,23847 claims
CSL BehringPrivigen$23,243$773,53973 claims
Grifols USA, LLCGamunex-C$28$581,90368 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$33,596$170,85026 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$26$31,561161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 652 neurology providers in Michigan.

Other neurology in East Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →